Alternate dosing of cetuximab for patients with metastatic colorectal cancer.
CONCLUSION: These data suggest that for patients for whom weekly treatment with cetuximab presents a substantial burden to their quality of life, q2w dosing of cetuximab is a viable treatment option with a benefit:risk profile similar to that of the weekly regimen.
PMID: 23745159 [PubMed]
Source: Gastrointestinal Cancer Research - Category: Cancer & Oncology Tags: Gastrointest Cancer Res Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Eloxatin | Erbitux | Gastroenterology | Study